Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 17, 2024
There
is
growing
recognition
of
the
potential
cannabis
to
treat
various
medical
conditions
and
symptoms,
such
as
chronic
pain,
spasticity,
epilepsy.
However,
one
biggest
challenges
assurance
a
standardized
product
that
contains
consistent
amount
its
main
psychoactive
substances
delta-9-tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
which
compliant
with
predetermined
specifications
for
these
compounds.
This
crucial
not
only
ensure
quality
dosage
patients
but
also
effectively
translate
research
findings
into
clinical
practice.
Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: April 23, 2024
Schizophrenia
is
a
serious
mental
health
disorder
that
confers
one
of
the
highest
mortality
rates
all
psychiatric
illnesses.
Although
disorder’s
psychotic
symptoms
are
treatable
with
conventional
antipsychotics,
they
remain
incurable.
Moreover,
medication
adherence
poor,
and
individuals
schizophrenia
choose
to
self-medicate
illicit
substances,
including
cannabis.
It
well-established
delta-9-tetrahydrocannabinol
(delta-9-THC)
component
cannabis
elicits
psychotomimetic
effects
at
high
doses;
worsens
schizophrenia-related
psychosis;
commonly
develops
into
use
in
schizophrenia;
increases
risk
earlier-onset
those
harboring
genetic
susceptibility.
However,
derivatives
such
as
cannabidiol
(CBD).
These
products
seem
alleviate
relieve
adverse
side
antipsychotic
medications.
Therefore,
notion
has
gained
traction
potential
utility
cannabis-derived
(CBD)
adjunct
treatment
reduce
schizophrenia-associated
psychosis
other
symptoms.
Currently,
preclinical
clinical
data
inconclusive.
The
present
review
distinguishes
mechanisms
underlying
vs.
cannabis-induced
reviews
evidence
for
delta-9-THC-mediated
exacerbation
CBD-mediated
amelioration
describes
approaches
incorporating
CBD
therapeutic
regimen
safe
efficacious
manner.
International Journal of Drug Policy,
Journal Year:
2024,
Volume and Issue:
128, P. 104457 - 104457
Published: May 20, 2024
The
legalization
of
cannabis
in
Canada
has
accelerated
the
need
for
a
standardized
approach
to
measuring
and
communicating
amount
delta-9-tetrahydrocannabinol
(THC)
products.
This
article
offers
an
overview
considerations
associated
with
establishing
implementing
standard
THC
unit
Canadian
context.
begins
by
discussing
applications
unit,
emphasizing
its
potential
use
product
labelling,
consumer
education,
reporting
surveillance.
then
examines
key
identifying
what
should
be
set
at,
specifically
within
context
country
regulated
commercial
market.
is
followed
discussion
additional
related
adoption
including
across
various
formats
modes
administration.
A
significant
focus
this
on
prioritizing
public
health
safety
informed
decision-making
among
adult
consumers
as
legal
market
evolves.
Collaboration
stakeholders,
such
government
agencies,
industry,
professionals,
highlighted
crucial
successful
transition
Canada's
unit.
Nature Mental Health,
Journal Year:
2024,
Volume and Issue:
2(7), P. 865 - 876
Published: June 3, 2024
Abstract
Cannabis,
one
of
the
most
widely
used
psychoactive
substances
worldwide,
can
give
rise
to
acute
cannabis-associated
psychotic
symptoms
(CAPS).
While
distinct
study
designs
have
been
examine
CAPS,
an
overarching
synthesis
existing
findings
has
not
yet
carried
forward.
To
that
end,
we
quantitatively
pooled
evidence
on
rates
and
predictors
CAPS
(
k
=
162
studies,
n
210,283
cannabis-exposed
individuals)
as
studied
in
(1)
observational
research,
(2)
experimental
tetrahydrocannabinol
(THC)
(3)
medicinal
cannabis
research.
We
found
varied
substantially
across
designs,
given
high
reported
by
research
(19%
21%,
respectively)
but
studies
(2%).
was
predicted
THC
administration
(for
example,
single
dose,
Cohen’s
d
0.7),
mental
health
liabilities
bipolar
disorder,
0.8),
dopamine
activity
0.4),
younger
age
−0.2),
female
gender
−0.09).
Neither
candidate
genes
COMT
,
AKT1
)
nor
other
demographic
variables
education)
meta-analytical
models.
The
results
reinforce
need
more
closely
monitor
adverse
cannabis-related
outcomes
vulnerable
individuals
these
may
benefit
from
harm-reduction
efforts.
Psychopharmacology,
Journal Year:
2024,
Volume and Issue:
241(6), P. 1125 - 1134
Published: Feb. 28, 2024
Abstract
Rationale
Attentional
bias
to
drug-related
stimuli
is
hypothesised
contribute
towards
addiction.
However,
the
acute
effects
of
Δ9-tetrahydrocannabinol
(THC)
on
attentional
cannabis
cues,
differential
response
in
adults
and
adolescents,
moderating
effect
cannabidiol
(CBD)
are
unknown.
Objectives
Our
study
investigated
(1)
vaporised
cannabis-related
images
adolescents
(2)
influences
age
CBD.
Methods
We
conducted
a
randomised,
double-blind,
placebo-controlled,
cross-over
where
three
weight-adjusted
preparations:
‘THC’
(8
mg
THC
for
75-kg
person),
‘THC
+
CBD’
24
CBD
person)
PLA
(matched
placebo).
Cannabis
was
administered
3
separate
days
48
participants,
who
used
0.5–3
days/week:
(12
females,
aged
16–17)
26–29).
Participants
completed
visual
probe
task
with
cues.
primary
outcome
stimuli,
measured
using
reaction
time
vs.
neutral
probe,
200-ms
trials.
Results
In
contrast
hypotheses,
attention
directed
away
from
cues
placebo,
there
main
drug
(
F
(2,92)
=
3.865,
p
0.024,
η
2
0.077),
indicating
administration
eliminated
this
bias.
There
no
significant
impact
nor
an
age-by-drug
interaction.
Conclusions
Acute
intoxication
evidence
compared
that
moderate
dose
altered
Trial
registration
This
listed
US
National
Library
Medicine
registered
ClinicalTrials.gov,
URL:
Do
Adolescents
Adults
Differ
Their
Response
Cannabis?—Full
Text
View—ClinicalTrials.gov
,
number:
NCT04851392.
Supportive Care in Cancer,
Journal Year:
2024,
Volume and Issue:
32(4)
Published: March 5, 2024
Abstract
Purpose
Cannabis
use
may
introduce
risks
and/or
benefits
among
people
living
with
cancer,
depending
on
product
type,
composition,
and
nature
of
its
use.
Patient
knowledge
tetrahydrocannabinol
(THC)
or
cannabidiol
(CBD)
concentration
could
provide
information
for
providers
about
cannabis
during
after
treatment
that
aide
in
risk
benefit
assessments.
This
study
aimed
to
examine
THC
CBD
patients
cancer
who
consume
cannabis,
factors
associated
cannabinoid
concentrations.
Methods
People
consumed
since
their
diagnosis
(
n
=
343)
completed
an
anonymous,
mixed-mode
survey.
Questions
assessed
usual
mode
delivery
(MOD),
THC/CBD
concentration,
how
source
acquisition,
current
use,
instruction
are
concentration.
Chi-square
separate
binary
logistic
regression
analyses
were
examined
weighted
reflect
the
Roswell
Park
patient
population.
Results
Less
than
20%
had
products
they
across
all
MOD
(smoking-
combustible
products,
vaping-
vaporized
(e-cigarettes),
edibles-eating
drinking
it,
oral-
taking
by
mouth
(pills)).
Source
acquisition
(smoking-AOR:4.6,
p
<
0.01,
vaping-AOR:5.8,
0.00,
edibles-AOR:2.6,
0.04),
(edibles-AOR:5.4,
vaping-AOR:
11.2,
oral-AOR:9.3,
0.00),
(vaping
only
AOR:4.2,
0.05)
found
be
variables
higher
Conclusion
Self-reported
statistically
differed
according
MOD,
instruction,
Psychological Medicine,
Journal Year:
2023,
Volume and Issue:
54(2), P. 245 - 255
Published: Oct. 26, 2023
Abstract
Cannabis
use
is
consistently
associated
with
both
increased
incidence
of
frank
psychotic
disorders
and
acute
exacerbations
symptoms
in
healthy
individuals
people
psychosis
spectrum
disorders.
Although
there
uncertainty
around
causality,
cannabis
may
be
one
a
few
modifiable
risk
factors
for
conversion
to
Clinical
High
Risk
Psychosis
(CHR-P)
syndromes,
characterized
by
functionally
impairing
distressing
subthreshold
symptoms.
To
date,
recommendations
beyond
abstinence
reduce
adverse
psychiatric
events
have
been
made.
This
narrative
review
synthesizes
existing
scientific
literature
on
cannabis'
psychotomimetic
effects
epidemiological
associations
CHR-P
bridge
the
gap
between
knowledge
practical
mental
health
intervention.
There
compelling
evidence
acutely
exacerbating
CHR-P,
but
its
impact
disorder
unclear.
Current
supports
harm
reduction
approach
reducing
frequency
psychotic-like
experiences,
though
whether
such
interventions
decrease
individuals'
remains
unknown.
Specific
include
use,
lowering
delta-9-tetrahydrocannabinol
content
favor
cannabidiol-only
products,
avoiding
products
inconsistent
potency
like
edibles,
enhancing
patient-provider
communication
about
utilizing
collaborative
individualized
therapeutic
approach.
Despite
surrounding
causal
association
disorders,
cautious
attempts
benefit
uninterested
abstinence.
Further
research
needed
clarify
practices
minimization
cannabis-related
risk.
Pharmacy,
Journal Year:
2024,
Volume and Issue:
12(4), P. 100 - 100
Published: June 27, 2024
Although
preliminary
evidence
suggests
Cannabis's
efficacy
in
symptom
control
for
anxiety
and
depression-psychiatric
disorders
that
significantly
impact
mental
health-much
remains
to
be
understood
about
its
effects
on
the
central
nervous
system
(CNS)
how
optimize
treatment
these
disorders.
This
study
aims
conduct
a
narrative
review
evaluate
pharmaceutical
care
treating
symptoms
of
depression
alongside
Cannabis
use,
focusing
safety
therapeutic
optimization.
We
seek
conceptualize
disorders,
quality,
identify
knowledge
gaps.
Twelve
articles
were
identified,
revealing
significant
gap
literature
regarding
integration
with
Cannabis-based
therapies,
specifically
depression.
Despite
growing
interest
relationship
between
health,
current
research
is
insufficient
comprehensive
understanding.
The
use
requires
further,
more
targeted
investigations.
underscores
importance
future
fill
existing
gaps,
providing
informed
insights
robust
guidelines
safe
effective
as
part
It
crucial
integrates
therapies
responsibly
improve
overall
well-being
patients.
Cannabis and Cannabinoid Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 26, 2024
The
chronic
effects
of
cannabidiol
(CBD)
supplementation
on
factors
that
could
impact
the
quality
life
(anxiety,
sleeping
quality,
memory,
etc.)
are
poorly
explored.
Hence,
aim
this
study
was
to
establish
whether
CBD
will
improve
self-reported
outcomes
related
life.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 17, 2024
There
is
growing
recognition
of
the
potential
cannabis
to
treat
various
medical
conditions
and
symptoms,
such
as
chronic
pain,
spasticity,
epilepsy.
However,
one
biggest
challenges
assurance
a
standardized
product
that
contains
consistent
amount
its
main
psychoactive
substances
delta-9-tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
which
compliant
with
predetermined
specifications
for
these
compounds.
This
crucial
not
only
ensure
quality
dosage
patients
but
also
effectively
translate
research
findings
into
clinical
practice.
